Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | KDM1A | O60341 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732541 | 1.00 | MAOA (0.61) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL29785655 | 1.00 | MAOA (0.61) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL801282 | 0.90 | MAOA (0.52) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL13280435 | 0.90 | MAOA (0.55) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL662711 | 0.89 | MAOA (0.57) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| Hydrochloric Acid SCHEMBL4799055 | 0.87 | MAOA (0.55) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL31706160 | 0.85 | MAOA (0.54) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL14862724 | 0.85 | MAOA (0.54) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 | |
| SCHEMBL5863593 | 0.84 | HPGD (0.55) | MAOAMAOBKDM1ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16464069 | 0.84 | MAOA (0.53) | MAOAMAOBKDM1ASMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | claimed |
| US-20180199577-A1 | COMPOSITIONS FOR CONTROL OF HEMIPTERAN INSECT STYLET SHEATH STRUCTURE FORMATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2018-07-19 | — | — | US | claimed |
| US-9949489-B2 | Methods for control of hemipteran insect stylet sheath structure formation | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2018-04-24 | — | — | US | claimed |
| US-20160316762-A1 | COMPOSITIONS AND METHODS FOR CONTROL OF HEMIPTERAN INSECT STYLET SHEATH STRUCTURE FORMATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2016-11-03 | — | — | US | claimed |
| WO-2007101284-A1 | REDOX FLOW BATTERY AND ELECTROLYTE SOLUTION FOR A EINE REDOX FLOW BATTERY | FUNKTIONSWERKSTOFFE FORSCHUNGS-UND ENTWICKLUNGS GMBH (AT) | 2007-09-13 | — | — | WO | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-12111313-B2 | Chelator-coated field effect transistor and devices and methods using same | Autonomous Medical Devices Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-11820973-B2 | Methods and system for interfering with viability of bacteria and related compounds and compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20160199437-A1 | THERAPEUTIC COMPOSITIONS INCLUDING IRON CHELATORS AND USES THEREOF | STEALTH BIOTHERAPEUTICS CORP (MC) | 2016-07-14 | — | — | US | disclosed |
| US-20160199437-A1 | THERAPEUTIC COMPOSITIONS INCLUDING IRON CHELATORS AND USES THEREOF | STEALTH BIOTHERAPEUTICS CORP (MC) | 2016-07-14 | — | — | US | disclosed |
| US-20160058843-A1 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS | TRUSTEES OF DARTMOUTH COLLEGE | 2016-03-03 | — | — | US | disclosed |
| EP-2702141-A2 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS | California Institute of Technology (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20130022578-A1 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2013-01-24 | — | — | US | disclosed |
| WO-2012149058-A2 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2007101284-A1 | REDOX FLOW BATTERY AND ELECTROLYTE SOLUTION FOR A EINE REDOX FLOW BATTERY | FUNKTIONSWERKSTOFFE FORSCHUNGS-UND ENTWICKLUNGS GMBH (AT) | 2007-09-13 | — | — | WO | disclosed |
| US-20050063903-A1 | cruciferous-related indole particulary diindolylmethanes, zinc/iron chelator, and optionally one or more of a zinc-binding histone deacetylase inhibitor, gallium or an EGFR antagonist, are administered simultaneously | BIORESPONSE L.L.C. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | MAOA 1400/4885MAOB 3144/4885KDM1A 1694/4885 |
| US-20160058843-A1 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS | MRPL21, BAX, SPOUT1 | MAOA 1794/4885MAOB 852/4885KDM1A 4547/4885 |
| US-20130022578-A1 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS | MRPL21, BAX, SPOUT1 | MAOA 1794/4885MAOB 852/4885KDM1A 4547/4885 |
| US-20160199437-A1 | THERAPEUTIC COMPOSITIONS INCLUDING IRON CHELATORS AND USES THEREOF | HAMP, SLC40A1, ARG2 | MAOA 1276/4885MAOB 1399/4885KDM1A 1335/4885 |
| US-20050063903-A1 | cruciferous-related indole particulary diindolylmethanes, zinc/iron chelator, and optionally one or more of a zinc-binding histone deacetylase inhibitor, gallium or an EGFR antagonist, are administered simultaneously | EZH2, EGFR, ZKSCAN2 | MAOA 916/4885MAOB 1709/4885KDM1A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.